TickerTalks
Browse all tickers →
TickerTalks›$NNOX
NNNNOX

Nano-X Imaging Ltd.

$NNOX·$74M·Medical - Devices·Healthcare
$0.77+8.3%YTD-62.8%1Y-81.0%
Price updated 25d ago·X counts updated 27d ago
NNNNOX
$NNOXNano-X Imaging Ltd.
$0.77+8.26%36 posts
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $NNOX on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

36X posts · last 7 days
No mention history yet
Mixed sentimentAI analysisGenerated by AI from underlying data5 posts analyzed · as of 2026-08-13

Nano-X Imaging news is dominated by a dilutive $8M registered direct offering priced at-the-market, and users note the Teledyne/Varex Imaging $1.1B deal as a positive sector read-through. NNOX also touts optimizing its medical-imaging AI framework for Intel Core Ultra processors with OpenVINO. Tone is neutral to modestly bullish on the tech but wary on the raise.

Read what X is saying about $NNOX

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $NNOX — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Broken storyStalledAI verdict · as of 2026-09-03

The move has stalled — likely just drifts unless something new shows up.

Nanox -80% TTM after $8M dilutive offering — Vertec exclusive reseller agreement fresh, but 3 law firms filed class actions.

Nano-X Imaging is an Israeli medical-imaging startup with an X-ray system and AI-CT platform. Down 63% YTD and 80% TTM at $0.76 — stalled with a heavy litigation overhang and continued dilution.

  • The core is very small and burning cash: Q1 revenue $4.3M (+53% YoY off a tiny base), -86% gross margin (unit economics broken at this scale), -343% operating margin, Q1 EPS -$0.20 (Q2 EPS -$0.20 vs -$0.14 est = 42.9% miss). FCF yield -67.3% and ROIC -44.3% are unsustainable-burn rates; analysts model 2026 revenue $25.9M and EPS -$0.62.
  • The catalyst mix is dominated by legal overhang: Pomerantz Law Firm Announces Class Action Against Nano-X Imaging Ltd. and Certain Officers. Bronstein, Gewirtz & Grossman Urges Investors to Act, Class Action Filed Alleging Investor claims. Portnoy Law Firm Announces Class Action on Behalf of Nano-X Imaging Investors. Three law firms with active class actions is a serious overhang.
  • The catalyst mix has a small positive: Nanox and Vertec Scientific Enter Exclusive Sales Reseller Agreement for the Commercialization of Nanox.AI Bone. Also NNOX optimizing its medical-imaging AI framework for Intel Core Ultra with OpenVINO. Director Erez Meltzer P-Purchase of just $9.7K on Aug 10 — trivial dollar amount but a genuine open-market purchase. $8M dilutive registered direct offering is the near-term overhang.

Breaks stall upward: Sept 9 Q2 above -$0.16 EPS plus Vertec reseller color. Deepens: a certified class action or a Nasdaq minimum-bid deficiency.

Agrees with X sentimentX is mixed with a modest bull framing on the Intel OpenVINO tech story plus Teledyne/Varex $1.1B sector read-through — but wary on the $8M dilutive raise. The mechanics support the caution: -80% TTM, three class actions filed, Q2 EPS missing by 42.9%, and stock at $0.76 approaching Nasdaq minimum bid thresholds. This is a broken story with dilution and litigation stacked, not a turnaround yet.

What to watch: September 9 Q2 earnings — EPS above -$0.16 and Vertec reseller commercial-revenue color. Also class action certification proceedings, and Nasdaq minimum-bid deficiency notices.

On the calendar: 2026-09-09 — Q2 earnings

Read the AI verdict on $NNOX

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Medical device company developing an affordable MEMS-based digital X-ray system for point-of-care imaging and teleradiology AI diagnostics.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Devices sits in its cycle right now — and what that implies for $NNOX.

Medical - Devices · Healthcare

Aging population demographics and AI-assisted device adoption (smart implants, continuous glucose monitors, digital health integration) are the long-cycle structural drivers. Reimbursement timing for new modalities (CMS coverage decisions) and procedure volume recovery from COVID-era deferred care shape the 2026 revenue trajectory.

What this means for $NNOX

Direct beneficiary — semiconductor products are directly in the AI capex supply chain; Nano-X Imaging Ltd.

Industry benchmark

19-name peer basket
+15.4%YTD
+25.0%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-1.0How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-44.3%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-423%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-67.3%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
5.2Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-51.9%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
-85.7%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.1Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026Jun 25, 2026$-0.20$-0.14-42.9%
Q1 2026Apr 20, 2026$-0.50$-0.23-117.4%
Q3 2025Nov 20, 2025$-0.21$-0.21+1.6%
Q2 2025Aug 12, 2025$-0.23$-0.17-31.4%
Next earningsWed, Sep 9·consensus EPS $-0.16

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$4.3M+53.1%-62.6%-343%$-0.20$-15.7M
Q4 FY25$3.7M+24.0%-97.3%-481%$-0.50$-12.5M
Q3 FY25$3.4M+13.7%-83.6%-413%$-0.21$-12.5M
Q2 FY25$3.0M+12.6%-107%-477%$-0.23$-10.4M

Forward consensus

5-year forecast · up to 3 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$25.9M$22.1M – $29.9M-$0.62-$0.68 – -$0.543
FY27$46.8M$42.5M – $51.9M-$0.38-$0.46 – -$0.293
FY28$87.3M$84.4M – $90.1M-$0.20-$0.22 – -$0.172
FY29$140.9M$129.4M – $153.6M$0.08$0.07 – $0.091
FY30$192.5M$176.8M – $209.9M$0.33$0.30 – $0.371

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.—Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.0%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-29.1%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-66.9%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

β1.275-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

BuyAug 10Erez MeltzerCEO9.4K sh$10KBuyJul 28Noga KainanDirector33.0K sh$30KBuyJul 27Dan S SuesskindDirector50.0K sh$47KBuyJul 27Erez MeltzerCEO36.0K sh$33KSellJun 10Erez AlroyDirector678 sh$1K
+ 1 other (1 return) in window

See when $NNOX insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

424B5Prospectus supplement (offering)Aug 7424B5
AI summary

NNOX (NNOX) filed a prospectus supplement (Form 424B5) on 2026-08-07 for an immediate offering of shares $1.00 per share, raising approximately $1.00. . Use of proceeds: general corporate purposes. This is dilutive capital activity happening now, distinct from a shelf registration — new shares will be issued. Investors should assess pricing relative to market and stated use of proceeds to evaluate dilution impact.

3New insider — initial holdingsAug 33
AI summary

Guy Nathansohn, incoming Chief Financial Officer of Nano-X Imaging Ltd. (NNOX), filed an initial Form 3 reporting no securities beneficially owned as of August 1, 2026. Administrative filing required under Section 16(a) of the Securities Exchange Act of 1934 upon becoming an officer. No market-moving content.

424B5Prospectus supplement (offering)Jul 24424B5
AI summary

NNOX filed a 424B5 prospectus supplement under an at-the-market (ATM) equity offering facility, offering up to $54M. Shares will be sold from time to time through sales agents at prevailing market prices, with no single fixed deal price or settlement date. This represents ongoing dilutive equity issuance; current remaining capacity under the facility is $54M. ATM programs allow flexible, market-timed capital raises but represent incremental dilution to existing shareholders.

3New insider — initial holdingsApr 303
3New insider — initial holdingsApr 93
3New insider — initial holdingsApr 73
3New insider — initial holdingsApr 73
+ 12 other (8 6-Ks · 3 13Gs · 1 20-F) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Nanox to Report Second Quarter 2026 Financial Results on September 9, 2026globenewswire.com·36d agoNanox and Vertec Scientific Enter Exclusive Sales Reseller Agreement for the Commercialization of Nanox.AI Bone Solution (HealthOST) in the United Kingdomglobenewswire.com·43d agoPomerantz Law Firm Announces the Filing of a Class Action Against Nano-X Imaging Ltd.and Certain Officers – NNOXglobenewswire.com·50d agoBronstein, Gewirtz & Grossman LLC Urges Nano-X Imaging Ltd. Investors to Act: Class Action Filed Alleging Investor Harmfeeds.newsfilecorp.com·50d agoPortnoy Law Firm Announces Class Action on Behalf of Nano-X Imaging Ltd. Investorsglobenewswire.com·50d ago

In themes

Explore the broader themes this ticker is being talked about under.

AI Precision Medicine

More in Medical - Devices

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$TMDX$BFLY$BIO$ABT$MDT$BSX$GEHC$SYK
Voices on X · last 7 days

No standout posts about $NNOX on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport